| Literature DB >> 23243413 |
Oanh H D Thang1, Erik H Serné, Muriel P C Grooteman, Yvo M Smulders, Piet M Ter Wee, Geert-Jan Tangelder, Menso J Nubé.
Abstract
BACKGROUND: Increasing age and advanced chronic kidney disease (CKD) are both associated with an attenuated vasodilator response of the skin microcirculation. In the present study, we investigated the effect of aging on microvascular reactivity in patients with advanced CKD.Entities:
Keywords: Aging; Chronic kidney disease; Endothelial function; Iontophoresis; Microcirculation
Year: 2012 PMID: 23243413 PMCID: PMC3521446 DOI: 10.1159/000343295
Source DB: PubMed Journal: Nephron Extra ISSN: 1664-5529
Demographic variables: groups were split into subgroups consisting of persons over and under 45 years
| Young healthy controls | Young advanced CKD | Old healthy controls | Old advanced CKD | ||
|---|---|---|---|---|---|
| (<45 years) | (<45 years) | (≥45 years) | (≥45 years) | ||
| Number (male/female) | 12 (7/5) | 11 (8/3) | 21 (12/9) | 41 (30/11) | |
| Mean age ± SD, years | 29.5 ± 5.4 | 34.9 ± 7.2 | 60.9 ± 7.1 | 61.1 ± 7.8 | |
| BMI | 23.7 ± 2.3 | 22.8 ± 4.7 | 24.7 ± 3.0 | 25.0 ± 3.4 | |
| Systolic blood pressure, mm Hg | 113 ± 13# | 128 ± 20 | 134 ± 15# | 145 ± 27# | |
| Diastolic blood pressure, mm Hg | 73 ± 8# | 77 ± 10 | 83 ± 7# | 83 ± 13# | |
| eGFR, ml/min | 116 [96–121] | 5 [0–7] | 85 [7–98] | 6 [3–12] | |
| Cause of renal disease | |||||
| Hypertension, n (%) | 5 (46) | 23 (56) | |||
| Hereditary disease, n (%) | 3 (27) | 10 (24) | |||
| Immune-complex glomerulonephritis, n (%) | 0 | 5 (12) | |||
| Others, n (%) | 3 (27) | 3 (7) | |||
| History of cardiovascular disease, n (%) | 0 | 0 | 0 | 13 (32) | |
| Smoking, n (%) | 0 | 4 (36) | 0 | 22 (54) | |
| Laboratory values | |||||
| Calcium, mmol/l | {2.2–2.6} | 2.31 ± 0.21 | 2.39 ± 0.14 | ||
| Phosphorus, mmol/l | {0.7–1.4} | 1.74 ± 0.44 | 1.62 ± 0.39 | ||
| Albumin, g/l | {35–52} | 38 ± 3.5 | 37.5 ± 3.7 | ||
| Parathyroid hormone, pmol/l | {0–11} | 17 (1–69) | 26 (17–37) | ||
| Bicarbonate, mmol/l | {22.0–26.0} | 24.1 ± 4.7 | 22.6 ± 3.0 | ||
| Hemoglobin, mmol/l | {7.5–11} | 7.5 ± 0.9 | 7.4 ± 0.9 |
Data are presented as mean ± SD or as median [interquartile range]. Reference values are in braces. # p < 0.05 young healthy controls vs. old healthy controls/old advanced CKD patients.
Demographic variables
| Healthy controls | CKD stage 4–5 | ESRD | |
|---|---|---|---|
| Number (male/female) | 33 (19/14) | 16 (10/6) | 36 (28/8) |
| Mean age ± SD, years | 49.5 ± 16.7 | 56.9 ± 11.5 | 55.0 ± 13.9 |
| BMI | 24.3 ± 2.7 | 25.9 ± 4.3 | 23.9 ± 3.4 |
| Systolic blood pressure, mm Hg | 126 ± 17* | 148 ± 30* | 139 ± 25 |
| Diastolic blood pressure, mm Hg | 79 ± 9 | 85 ± 16 | 80 ± 10 |
| eGFR, ml/min/1.73 m2 | 90 [76–108] | 11 [8–13] | 4 [0–6] |
| History of cardiovascular disease, n (%) | 0 | 4 (25) | 9 (25) |
| Dialysis vintage, years | |||
| Peritoneal dialysis patients (n = 16) | 1.76 ± 1.06 | ||
| Hemodialysis patients (n = 20) | 2.20 ± 2.51 | ||
| Smoking, n (%) | 0 | 8 (50) | 18 (50) |
| Medication | |||
| Diuretic use, n (%) | 7 (44) | 18 (50) | |
| Inhibitors of RAAS, n (%) | 13 (81) | 25 (69) | |
| Calcium antagonist, n (%) | 10 (63) | 12 (33) | |
| Beta-blocker, n (%) | 8 (50) | 23 (64) | |
| Calcium carbonate, n (%) | 4 (25) | 22 (61) | |
| Sevelamer, n (%) | 5 (31) | 25 (69) | |
| Lanthanum carbonate, n (%) | 0 | 9 (25) |
Data are presented as mean ± SD or as median [interquartile range]. RAAS = Renin angiotensin aldosterone system. * p < 0.01 healthy controls vs. CKD stage 4–5.
Fig. 1ACh- and SNP-mediated vasodilations, defined as percentage increase from baseline to the final 2 min of the plateau phase. A box represents the 25th–75th percentile range, the whiskers represent the 10th–90th percentile range and the line within the boxes the median value.
Correlations between demographic and clinical parameters with microvascular function (log ACh-mediated and log SNP-mediated vasodilation) by linear regression analysis in healthy controls (n = 33)
| Determinant | B | 95% CI | p | r |
|---|---|---|---|---|
| Age, years | −0.01 | −0.02 to −0.002 | −0.41 | |
| Female gender | −0.09 | −0.41 to 0.24 | 0.58 | −0.10 |
| eGFR, ml/min | 0.01 | 0.002 to 0.02 | 0.44 | |
| BMI | −0.03 | −0.09 to 0.03 | 0.31 | −0.18 |
| Systolic blood pressure, mm Hg | −0.01 | −0.02 to −0.001 | −0.39 | |
| Diastolic blood pressure, mm Hg | −0.01 | −0.03 to 0.01 | 0.30 | −0.19 |
| Age, years | −0.01 | −0.02 to −0.001 | −0.38 | |
| Female gender | 0.31 | 0.05 to 0.57 | 0.40 | |
| eGFR, ml/min | 0.01 | −0.002 to 0.01 | 0.13 | 0.29 |
| BMI | −0.02 | −0.07 to 0.03 | 0.38 | −0.16 |
| Systolic blood pressure, mm Hg | −0.01 | −0.02 to −0.004 | −0.50 | |
| Diastolic blood pressure, mm Hg | −0.02 | −0.03 to −0.002 | 0.03 | −0.39 |
Associations between demographic and clinical parameters with microvascular function (log ACh-mediated and log SNP-mediated vasodilation) by linear regression analysis in patients with advanced CKD (n = 52)
| Determinant | B | 95% CI | p | r |
|---|---|---|---|---|
| Age, years | 0.02 | 0.00–0.03 | 0.28 | |
| Female gender | 0.15 | −0.29–0.59 | 0.49 | 0.10 |
| eGFR, ml/min | 0.01 | −0.03–0.05 | 0.57 | 0.08 |
| BMI | −0.04 | −0.09–0.01 | 0.09 | −0.24 |
| Systolic blood pressure, mm Hg | 0.01 | −0.001–0.01 | 0.12 | 0.22 |
| Diastolic blood pressure, mm Hg | 0.02 | 0.01–0.04 | 0.41 | |
| Phosphate, mmol/l | −0.26 | −0.75–0.23 | 0.30 | −0.15 |
| Calcium, mmol/l | 0.65 | −0.56–1.87 | 0.28 | 0.15 |
| Age, years | −0.002 | −0.01–0.01 | 0.74 | −0.05 |
| Female gender | 0.04 | −0.25–0.33 | 0.80 | 0.04 |
| eGFR, ml/min | 0.01 | −0.02–0.04 | 0.53 | 0.09 |
| BMI | −0.03 | −0.06–0.01 | 0.10 | −0.23 |
| Systolic blood pressure, mm Hg | 0.00 | −0.01–0.004 | 0.84 | −0.03 |
| Diastolic blood pressure, mm Hg | 0.003 | −0.01–0.01 | 0.61 | 0.07 |
| Phosphate, mmol/l | −0.01 | −0.34–0.31 | 0.95 | −0.01 |
| Calcium, mmol/l | −0.48 | −1.27–0.31 | 0.23 | −0.17 |